Status: Recruiting
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.
Participants needed: 300
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Grey Wolf TherapeuticsUpdated: Jan 28, 2026Locations: 29
Eligibility criteria
Provision of written informed consent. [+24]
Prior therapy with an ERAP1 inhibitor. [+33]